AlloVir develops allogeneic, virus-specific T cell (VST) therapy candidates targeting 11 different viruses for treatment or prevention.

AlloVir

AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The company’s technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVir’s technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

Cancer Prevention and Research Institute of Texas

Redmile Group

EcoR1 Capital

ElevateBio

F2 Ventures

Gilead Sciences

GMT Capital

Invus

Kite Pharma

Samsara BioCapital

Leerink Partners

Fidelity Management and Research Company

Today AlloVir announced that it will stop three ongoing Phase 3 trials of its lead multi-virus-specific T cell therapy, posoleucel, for futility. Learn more here: https://lnkd.in/eZ7NWu3A

Posoleucel is an investigational #Tcell therapy designed to target six common viruses that can have devastating consequences for people with immune deficiency. 

This T cell therapy is a living investigational drug, comprised of both CD8+ and CD4+ virus-specific T cells which expand in the presence of viral antigens, selectively killing the virus-infected cells, then contract once the virus is no longer detected.

Explore the science: https://lnkd.in/ebf_JHNM

#viraldisease #biotechnology #virology #innovation

Earlier this week our team gathered to celebrate the upcoming holiday season and reflect on our accomplishments in 2023. We are excited for the progress we have made this year with our lead investigational therapy, posoleucel.
#ExCELLenceAtAlloVir #celebration #biotechnology #culture

In case you missed it, AlloVir's CEO, Diana Brainard, participated in a fireside chat during the @PiperSandler 35th Annual Healthcare Conference. To learn more about AlloVir and our VST platform, listen here: https://lnkd.in/euE4njdu

#biotechnology #celltherapy #investmentbanking

November is the time of year when we take a moment to pause and reflect on all we are grateful for in our lives.  This year, we asked our colleagues at AlloVir to let us know what they are thankful for.  See some of their responses below! #ExCELLenceAtAlloVir #biotechnology #employeeengagement

Join our CEO, Diana Brainard, MD, for a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday November 28th, at 10AM ET.

Learn more here: https://lnkd.in/euE4njdu

#biotechnology #investmentbanking

Our CEO, Diana Brainard, MD, sat down with biotech reporter Luke Timmerman for his podcast, “The Long Run with Luke Timmerman” to discuss her background and the impact virus-specific T cells could have on infectious diseases.

Listen to the episode here: https://lnkd.in/efuEmT9Q

On Veteran's Day, we would like to take a moment to recognize the brave individuals who have helped protect our country and keep us safe at home and abroad. 

Thank you for your service. #veteransday

More than 80% of allo-HCT patients reactivate one or more viruses and with limited to no treatment options when patients do reactivate a virus, there is a high unmet need within this population. 

Our investigational T cell therapy, posoleucel, seeks to treat or prevent six common but devastating viruses: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus, (EBV), human herpesvirus (HHV-6), and JC virus (JCV).

Posoleucel has the potential to transform care for transplant recipients.
#celltherapy #innovation #biotechnology

Join Francesca Cardarelli, MD, FAST, AlloVir’s Senior Director of Clinical Development, on Saturday, November 4th at American Society of Nephrology's #KidneyWk.

Dr. Cardarelli will present data from AlloVir's Phase 2 trial of our multi-virus specific #tcell therapy, posoleucel, in kidney transplant patients with BK viremia. #clinicaltrials

DNSSEC

Google Maps

Amazon

Microsoft Exchange Online

Office 365 Mail

GoDaddy DNS

Google Maps API

AWS Global Accelerator

Google Maps for Work

Co-Founder and Chief Scientific Officer

Ann Leen

Senior Vice President, Chief Accounting Officer (CAO)

Brett Hagen

Executive Chairman

David L. Hallal

Chief Executive Officer

Diana Brainard

Founder IBIOC Consulting

Haifa Hamdi

President and CFO

Vikas Sinha

Vice President, Head of Safety

Badrish Patel

SVP Technical Operations

Dana Alexander

Vice President

Iain Fraser

SVP, Development Strategy & Operations

Lori Payton

Elizabeth Stoner

Jeffrey Bornstein

Juan Vera

Chief Product Development Officer

Co-Founder & Chief Scientific Officer

Edward Miller

General Counse & Secretary

Melissa Stundick

Senior Vice President Business Development

President & CFO

Biotechnology Companies (Top 10K)

Pharmaceutical Female Founded Companies

Biotechnology Public Companies With Less Than $10M in Revenue

Greater Houston Area Companies With Fewer Than 1000 Employees (Top 10K)

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials.

Post-IPO Equity - AlloVir

Fidelity

Series B - AlloVir

Venture Round - AlloVir

Grant - AlloVir

Houston

Texas

United States

North America

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, ALVR, PULM, ENTO on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IPXX, YOTA, ALVR on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALVR, CDMO, EMKR on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AE, EMKR, STAF, ALVR on Behalf of Shareholders

Allovir's general counsel sells over $1,000 in stock

Allovir executive sells over $2500 in company stock

Allovir CEO Diana Brainard sells shares worth over $4,000

Allovir CEO Diana Brainard sells shares worth over $4,000 By Investing.com

Allovir CEO Diana Brainard sells shares worth over $2,300 By Investing.com

An off-the-shelf T cell therapy targeting six viruses: adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

A multi-virus specific T cell therapy targeting respiratory viruses: human metapneumovirus, influenza, parainfluenza virus, and respiratory syncytial virus.

A virus-specific T cell therapy targeting hepatitis B virus for treatment and potential cure of chronic HBV infections.

news impact assignment basic	general
public peers	general	Sep 3, 2024 11:53 PM	9b3ecdbb
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 3, 2024 11:57 PM	773fd093
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	44cf3508
crunchbase profile	general	Nov 22, 2024 3:12 PM	488f3a06
li profile	general	Sep 3, 2024 11:53 PM	883c9655
translate crunchbase fundingrounds	general	Nov 22, 2024 8:38 PM	894516be
peers	general	Sep 3, 2024 11:53 PM	0897409c
news basic	general	Sep 3, 2024 11:53 PM	2ced0922
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ALLOVIR

AlloVir